A5081487159- Rheumatoid Arthritis Research and Therapies
- Systemic Lupus Erythematosus Research
- Spondyloarthritis Studies and Treatments
- Autoimmune and Inflammatory Disorders Research
- Chronic Lymphocytic Leukemia Research
- Biosimilars and Bioanalytical Methods
- Psoriasis: Treatment and Pathogenesis
- Monoclonal and Polyclonal Antibodies Research
- COVID-19 Clinical Research Studies
- Lymphoma Diagnosis and Treatment
- SARS-CoV-2 and COVID-19 Research
- Long-Term Effects of COVID-19
- Cytokine Signaling Pathways and Interactions
- Inflammasome and immune disorders
- Viral Infections and Immunology Research
- Health Systems, Economic Evaluations, Quality of Life
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Immunodeficiency and Autoimmune Disorders
- Tuberculosis Research and Epidemiology
- Peripheral Neuropathies and Disorders
- Bone and Joint Diseases
- Hepatitis C virus research
- Musculoskeletal synovial abnormalities and treatments
- Ocular Diseases and Behçet’s Syndrome
Istituto Ortopedico Gaetano Pini
2016-2025
University of Milan
2013-2025
NHS Greater Glasgow and Clyde
2023
Peking University
2023
National Institute of Geriatrics, Rheumatology and Rehabilitation
2023
Novartis (Germany)
2023
Academic College of Tel Aviv-Yafo
2023
Tel Aviv University
2023
Tel Aviv Sourasky Medical Center
2023
Pfizer (United States)
2023
Obesity is a mild, long-lasting inflammatory disease and, as such, could increase the burden of rheumatoid arthritis (RA). The study aim was to determine whether obesity represents risk factor for poor remission rate in RA patients requiring anti-tumor necrosis α (anti-TNFα) therapy progressive and active despite treatment with methotrexate or other disease-modifying antirheumatic drugs.Patients were identified from 15 outpatient clinics university hospitals Italy taking part Gruppo Italiano...
A cohort of rheumatoid arthritis (RA) patients in the Lombardy Rheumatology Network (LOHREN) registry and receiving anti‐TNF therapy was evaluated after 6, 12, 24, 36 months. Of 1114 1064 met clinical criteria for inclusion with 519 infliximab, 303 adalimumab, 242 etanercept. The therapeutic survival curve these showed that likelihood continuing 78.8% 12 months, 65.2% 24 52.9% a risk dropout similar inefficacy adverse events. There were 405 discontinuations (38.1%): 180 (16.9%) due to...
To describe the incidence and severity of coronavirus disease 2019 (COVID-19) in patients with rheumatic diseases treated targeted synthetic or biologic disease-modifying antirheumatic drugs (DMARDs) compared that general population living same Italian region.Patients followed up at 2 rheumatology referral centers Lombardy from February 25, 2020 to April 10, were invited participate a survey designed identify who had confirmed COVID-19, close contact others symptoms infection, detect changes...
Rheumatoid arthritis (RA) is associated with accelerated atherosclerosis. The reduction in cardiovascular risk that induced by methotrexate (MTX) and anti-tumor necrosis factor α agents RA considered secondary to their anti-inflammatory action, but effects on serum lipoprotein function foam cell formation are unknown. reduced capacity of high-density (HDL) promote cholesterol efflux the increased cholesterol-loading (CLC) demonstrated may contribute development. aim this study was...
Little is known about the safety of SARS-CoV-2 vaccination in patients with rheumatic musculoskeletal disease (RMD). We evaluated occurrence adverse events following immunization (AEFI) RMD and heathy subjects who received anti-SARS-CoV-2 mRNA vaccine.
To evaluate the 12-year survival of first tumor necrosis factor inhibitor (TNFi) treatment in a cohort rheumatoid arthritis (RA) patients, comparing between-groups discontinuation rates for infliximab, etanercept, and adalimumab.RA patients treated with their TNFi were investigated from local registry. Before after adjusting propensity scores, overall by individual drug retention was evaluated. Drug calculated using Kaplan-Meier method compared Cox extended model. Subanalyses performed...
The aim of this study was to evaluate the survival on treatment with second-line biologic therapy in RA patient non-responders TNF inhibitors (TNFis) by comparing treatments a second anti-TNF (cycling strategy) or agents different mechanism action (MoA; swap strategy).RA patients treated biologics since 1999 who stopped first-line TNFi and started biotherapy were included cohort study. After adjusting for propensity scores, drug retention rates calculated using Kaplan-Meier method. log-rank...
To study, in a real-life setting, the construct validity, reliability, and interpretability of 12-item Psoriatic Arthritis Impact Disease (PsAID-12) questionnaire patients with psoriatic arthritis (PsA).In 144 consecutive PsA (81 men 63 women, mean age 51.4 ± 12.8 yrs, 77 receiving biologic treatment), PsAID-12 other patient-reported outcomes (PRO) were collected, such as Dermatology Life Quality Index. Each patient underwent articular skin assessment.Construct validity: Factor analysis...